Literature DB >> 17766480

Proinflammatory and vasodilator effects of nociceptin/orphanin FQ in the rat mesenteric microcirculation are mediated by histamine.

Zoë L S Brookes1, Emily N Stedman, Remo Guerrini, Bethan K Lawton, Girolamo Calo, David G Lambert.   

Abstract

Nociceptin/orphanin FQ (N/OFQ) is the endogenous ligand for the N/OFQ peptide receptor (NOP). N/OFQ causes hypotension and vasodilation, and we aimed to determine the role of histamine in inflammatory microvascular responses to N/OFQ. Male Wistar rats (220-300 g, n = 72) were anesthetized with thiopental (30 mg/kg bolus, 40-90 mg x kg(-1) x h(-1) iv), and the mesentery was prepared for fluorescent intravital microscopy using fluorescein isothiocyanate-conjugated BSA (FITC-BSA, 0.25 ml/100 g iv) or 1 microm fluorescently labeled microspheres. N/OFQ (0.6-60 nmol/kg iv) caused hypotension (SAP, baseline: 154 +/- 11 mmHg, 15 nmol/kg N/OFQ: 112 +/- 10 mmHg, P = 0.009), vasodilation (venules: 23.9 +/- 1.2 microm, 26.7 +/- 1.2 microm, P = 0.006), macromolecular leak (interstitial gray level FITC-BSA: 103.7 +/- 3.4, 123.5 +/- 11.8, P = 0.009), and leukocyte adhesion (2.0 +/- 0.9, 15.2 +/- 0.9/100 microm, P = 0.036). Microsphere velocity also decreased (venules: 1,230 +/- 370 microm/s, P = 0.037), but there were no significant changes in blood flow. Flow cytometry measured a concurrent increase in neutrophil expression of cd11b with N/OFQ vs. controls (Geo mean fluorescence: 4.19 +/- 0.13 vs. 2.06 +/- 0.38, P < 0.05). The NOP antagonist [Nphe(1),Arg(14),Lys(15)]N/OFQ-NH(2) (UFP-101; 60 and 150 nmol/kg iv), H(1) and H(2)antagonists pyrilamine (mepyramine, 1 mg/kg iv) and ranitidine (1 mg/kg iv), and mast cell stabilizer cromolyn (1 mg x kg(-1) x min(-1)) also abolished vasodilation and macromolecular leak to N/OFQ in vivo (P < 0.05), but did not affect hypotension. Isolated mesenteric arteries (approximately 200 microm, n = 25) preconstricted with U-46619 were also mounted on a pressure myograph (60 mmHg), and both intraluminally and extraluminally administered N/OFQ (10(-5) M) caused dilation, inhibited by pyrilamine in the extraluminal but not the intraluminal (control: -6.9 +/- 3.8%; N/OFQ: 32.6 +/- 8.4%; pyrilamine: 31.5 +/- 6.8%, n = 18, P < 0.05) experiments. We conclude that, in vivo, mesenteric microvascular dilation and macromolecular leak occur via N/OFQ-NOP-mediated release of histamine from mast cells. Therefore, N/OFQ-NOP has an important role in microvascular inflammation, and this may be targeted during disease, particularly as we have proven that UFP-101 is an effective antagonist of microvascular responses in vivo.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17766480     DOI: 10.1152/ajpheart.00448.2007

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  11 in total

Review 1.  Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists.

Authors:  W Schröder; D G Lambert; M C Ko; T Koch
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

2.  Hepatoprotective and anti-tumor effects of targeting MMP-9 in hepatocellular carcinoma and its relation to vascular invasion markers.

Authors:  Mohammed A F Elewa; Mohammed M Al-Gayyar; Mona F Schaalan; Khaled H Abd El Galil; Mohamed A Ebrahim; Mamdouh M El-Shishtawy
Journal:  Clin Exp Metastasis       Date:  2015-05-22       Impact factor: 5.150

3.  Functional pharmacological characterization of SER100 in cardiovascular health and disease.

Authors:  Inmaculada C Villar; Kristen J Bubb; Amie J Moyes; Eva Steiness; Trygve Gulbrandsen; Finn Olav Levy; Adrian J Hobbs
Journal:  Br J Pharmacol       Date:  2016-11-01       Impact factor: 8.739

4.  Nociceptin receptor signaling in sympathetic neurons from septic rats.

Authors:  Lacee J Laufenberg; Gregory E Weller; Charles H Lang; Victor Ruiz-Velasco
Journal:  J Surg Res       Date:  2013-04-11       Impact factor: 2.192

5.  The nociceptin/orphanin FQ-NOP receptor antagonist effects on an animal model of sepsis.

Authors:  Dickson Carvalho; Fabricia Petronilho; Francieli Vuolo; Roberta Albino Machado; Larissa Constantino; Remo Guerrini; Girolamo Calo; Elaine Cristina Gavioli; Emílio Luiz Streck; Felipe Dal-Pizzol
Journal:  Intensive Care Med       Date:  2008-10-10       Impact factor: 17.440

Review 6.  Nociceptin system as a target in sepsis?

Authors:  Róisín Thomas; Cordula Stover; David G Lambert; Jonathan P Thompson
Journal:  J Anesth       Date:  2014-04-12       Impact factor: 2.078

7.  Pkd2 mesenteric vessels exhibit a primary defect in endothelium-dependent vasodilatation restored by rosiglitazone.

Authors:  Zoë L S Brookes; Lewis Ruff; Viralkumar S Upadhyay; Linghong Huang; Sony Prasad; Tirupa Solanky; Surya M Nauli; Albert C M Ong
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-10-26       Impact factor: 4.733

8.  NOP Receptor Ligands as Potential Agents for Inflammatory and Autoimmune Diseases.

Authors:  Elaine C Gavioli; Pedro R T Romão
Journal:  J Amino Acids       Date:  2011-11-17

9.  Angiopoietin-1 variant reduces LPS-induced microvascular dysfunction in a murine model of sepsis.

Authors:  Alessio Alfieri; Jay J Watson; Richard A Kammerer; Mohammed Tasab; Pavlos Progias; Kimberly Reeves; Nicola J Brown; Zoe L Brookes
Journal:  Crit Care       Date:  2012-10-04       Impact factor: 9.097

10.  The nociceptin/orphanin FQ receptor antagonist UFP-101 reduces microvascular inflammation to lipopolysaccharide in vivo.

Authors:  Zoë L S Brookes; Emily N Stedman; Nicola J Brown; Christopher P Hebbes; Remo Guerrini; Girolamo Calo; Charles S Reilly; David G Lambert
Journal:  PLoS One       Date:  2013-09-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.